Infinity Pharmaceuticals Inc.

05/06/2021 | Press release | Distributed by Public on 05/06/2021 05:39

Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

Infinity Announces the Date of Its First Quarter 2021 Financial Results Conference Call and Webcast

May 6, 2021 at 7:35 AM EDT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 6, 2021-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Thursday, May 13th 2021 at 4:30pm ET to report its financial results for the first quarter of 2021.

Conference call & Webcast Details

Date:

Thursday, May 13

Time:

4:30 pm Eastern Time

Webcast:

https://edge.media-server.com/mmc/p/dtagi4zo

Toll Free:

(877) 316-5293

International:

(631) 291-4526

ID Number:

9988449

A live webcast of the conference call can be accessed in the Investors/Media section of Infinity's website at www.infi.com and will be available on Infinity's website for 30 days following the event.

About Infinity and Eganelisib

Infinity Pharmaceuticals, Inc. ('Infinity' or the 'Company'), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic that addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210506005272/en/

Investor Relations:
Irina Koffler
LifeSci Advisors, LLC
646-970-4681
[email protected]

Source: Infinity Pharmaceuticals, Inc.